{"id":742166,"date":"2012-11-27T08:30:00","date_gmt":"2012-11-27T08:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-announce-acceptance-for-review-of-european-marketing-authorization-applications-for-vintafolide-and-companion-diagnostic-etarfolatide-for-folate-receptor-positive-platinum-resistant\/"},"modified":"2023-03-22T00:04:20","modified_gmt":"2023-03-22T04:04:20","slug":"merck-and-endocyte-announce-acceptance-for-review-of-european-marketing-authorization-applications-for-vintafolide-and-companion-diagnostic-etarfolatide-for-folate-receptor-positive-platinum-resistant","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-announce-acceptance-for-review-of-european-marketing-authorization-applications-for-vintafolide-and-companion-diagnostic-etarfolatide-for-folate-receptor-positive-platinum-resistant\/","title":{"rendered":"Merck and Endocyte Announce Acceptance for Review of European Marketing Authorization Applications for Vintafolide and Companion Diagnostic Etarfolatide for Folate-Receptor Positive Platinum-Resistant Ovarian Cancer"},"content":{"rendered":"<p class=\"bwalignc\">       Novel personalized treatment approach targets folate receptors on        cancer cells     <\/p>\n<p>Merck, known as MSD outside the United States and Canada (NYSE: MRK),<br \/>\n      and Endocyte Inc. (NASDAQ: ECYT), today announced that the European<br \/>\n      Medicines Agency (EMA) has accepted for review the marketing<br \/>\n      authorization application (MAA) filings for the novel investigational<br \/>\n      cancer candidate vintafolide (MK-8109\/EC145) and investigational<br \/>\n      companion diagnostic imaging agent etarfolatide (EC20), for the targeted<br \/>\n      treatment of patients with folate-receptor positive platinum-resistant<br \/>\n      ovarian cancer in combination with pegylated liposomal doxorubicin<br \/>\n      (PLD). Both vintafolide and etarfolatide have been granted orphan drug<br \/>\n      status by the European Commission.\n    <\/p>\n<p>\n      Vintafolide is a proprietary, injectable, conjugate consisting of folate<br \/>\n      (vitamin B9) linked to a potent vinca alkaloid anti-cancer agent,<br \/>\n      desacetylvinblastine hydrazide (DAVLBH). Folate is essential for cell<br \/>\n      division, and cancer cells generally consume higher levels of folate<br \/>\n      than normal cells to fuel their rapid rate of growth and division. In<br \/>\n      order to satisfy the demand for folate, some cancer cell types \u2013<br \/>\n      including ovarian \u2013 express high concentrations of folate receptors on<br \/>\n      their surface. Vintafolide is designed to exploit this characteristic by<br \/>\n      selectively targeting the folate receptor to deliver the anti-cancer<br \/>\n      agent DAVLBH intracellular to the tumor.\n    <\/p>\n<p>\n      \u201cThe acceptance of the EMA filing for vintafolide is an important<br \/>\n      milestone for Merck and Endocyte,\u201d said Gary Gilliland, M.D., Ph.D.,<br \/>\n      senior vice president and oncology franchise head, Merck Research<br \/>\n      Laboratories. \u201cVintafolide is designed to preferentially target cancer<br \/>\n      cells that actively take up folate via the folate receptor.\u201d\n    <\/p>\n<p>\n      The MAA filings are supported by four clinical studies: a Phase I study<br \/>\n      in solid tumors, two single-agent, single-arm Phase II studies in<br \/>\n      ovarian cancer and non-small cell lung cancer, and the PRECEDENT trial,<br \/>\n      a randomized Phase IIb study in patients with platinum-resistant ovarian<br \/>\n      cancer. The application is being submitted for conditional approval on<br \/>\n      the basis that the results from the Phase II studies fulfill an unmet<br \/>\n      medical need.\n    <\/p>\n<p>\n      Vintafolide is currently being evaluated in a Phase III randomized,<br \/>\n      double-blind clinical trial for platinum-resistant ovarian cancer<br \/>\n      (PROCEED trial). The PROCEED trial is evaluating vintafolide in<br \/>\n      combination with PLD compared to PLD plus placebo for the treatment of<br \/>\n      folate-receptor positive platinum-resistant ovarian cancer. This trial<br \/>\n      also employs the companion diagnostic imaging agent etarfolatide, which<br \/>\n      is a molecular imaging agent that is being developed as a non-invasive<br \/>\n      method to identify tumors that over-express folate receptors. The<br \/>\n      primary endpoint of the trial is progression-free survival as measured<br \/>\n      by RECIST v 1.1 (Response Evaluation Criteria In Solid Tumor) criteria<br \/>\n      in patients with all target tumor lesions positive as assessed by<br \/>\n      etarfolatide imaging. Overall survival is a secondary endpoint. The<br \/>\n      trial anticipates recruiting patients at approximately 150 sites in the<br \/>\n      United States, Canada, Europe and Asia. For further information<br \/>\n      regarding these trials, please visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.clinicaltrials.gov&amp;esheet=50488910&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.clinicaltrials.gov&amp;index=1&amp;md5=c065bb70418b9f866f22fc918db30f60\">http:\/\/www.clinicaltrials.gov<\/a>.\n    <\/p>\n<p>\n      \u201cWe are pleased with the acceptance of the applications in Europe as an<br \/>\n      important milestone towards providing a new treatment option targeted<br \/>\n      for folate-receptor positive platinum-resistant ovarian cancer<br \/>\n      patients,\u201d said Ron Ellis, Endocyte\u2019s president and CEO. \u201cThe use of<br \/>\n      etarfolatide as a companion diagnostic imaging agent to guide patient<br \/>\n      selection for vintafolide is a key element in implementing a<br \/>\n      personalized medicine approach to treating ovarian cancer.\u201d\n    <\/p>\n<p>\n      As part of an exclusive license agreement with Endocyte, Merck, through<br \/>\n      an MSD affiliate, is responsible for the development and worldwide<br \/>\n      commercialization of vintafolide in oncology. Endocyte intends to<br \/>\n      co-promote vintafolide in the United States, and is responsible for the<br \/>\n      development, manufacture and commercialization of etarfolatide<br \/>\n      worldwide. Merck will pay Endocyte a $5 million milestone payment for<br \/>\n      the EMA filing acceptance.\n    <\/p>\n<p>\n      <b>About Folate-Receptor Positive Platinum-Resistant Ovarian Cancer<\/b>\n    <\/p>\n<p>\n      In 2012, it is estimated that there will be 22,280 new cases of ovarian<br \/>\n      cancer in the United States and over 40,000 new cases in the European<br \/>\n      Union. Ovarian cancer causes more deaths than any other cancer of the<br \/>\n      female reproductive system. Overall, approximately 80 percent of<br \/>\n      patients relapse after first-line platinum-based chemotherapy.<br \/>\n      Platinum-resistant ovarian cancer is a challenging disease with a high<br \/>\n      unmet need. This type of cancer recurs within six months of completion<br \/>\n      with a platinum-containing regimen, the standard of care for ovarian<br \/>\n      cancer. An estimated 80 percent of platinum-resistant ovarian cancer<br \/>\n      patients have been found to have folate-receptor positive disease, and<br \/>\n      40 percent express the receptor in all of their target tumor lesions.<br \/>\n      Compared to patients who do not express folate receptors on their<br \/>\n      tumors, folate-receptor positive patients have been shown to have a<br \/>\n      poorer overall prognosis.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today\u2019s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=50488910&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=d5ce631d2f933b39d327345c7401a444\">vip2-msd.com\/merckcom-migrated<\/a>.\n    <\/p>\n<p>\n      <b>About Endocyte<\/b>\n    <\/p>\n<p>\n      Endocyte is a biopharmaceutical company developing targeted therapies<br \/>\n      for the treatment of cancer and other serious diseases. Endocyte uses<br \/>\n      its proprietary technology to create novel Small Molecule Drug<br \/>\n      Conjugates (SMDCs) and companion imaging diagnostics for personalized<br \/>\n      targeted therapies. The company\u2019s SMDCs actively target receptors that<br \/>\n      are over-expressed on diseased cells, relative to healthy cells, and<br \/>\n      deliver highly potent drugs into these cells. Patients can be identified<br \/>\n      prior to the treatment with the corresponding companion imaging<br \/>\n      diagnostic. For more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.endocyte.com&amp;esheet=50488910&amp;lan=en-US&amp;anchor=www.endocyte.com&amp;index=3&amp;md5=0a43b94b3dc95c823f0026c4d6af29e4\">www.endocyte.com<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. Such statements may include,<br \/>\n      but are not limited to, statements about the benefits of the merger<br \/>\n      between Merck and Schering-Plough, including future financial and<br \/>\n      operating results, the combined company\u2019s plans, objectives,<br \/>\n      expectations and intentions and other statements that are not historical<br \/>\n      facts. Such statements are based upon the current beliefs and<br \/>\n      expectations of Merck\u2019s management and are subject to significant risks<br \/>\n      and uncertainties. Actual results may differ from those set forth in the<br \/>\n      forward-looking statements.\n    <\/p>\n<p>\n      The following factors, among others, could cause actual results to<br \/>\n      differ from those set forth in the forward-looking statements: the<br \/>\n      possibility that all of the expected synergies from the merger of Merck<br \/>\n      and Schering-Plough will not be realized, or will not be realized within<br \/>\n      the expected time period; the impact of pharmaceutical industry<br \/>\n      regulation and health care legislation in the United States and<br \/>\n      internationally; Merck\u2019s ability to accurately predict future market<br \/>\n      conditions; dependence on the effectiveness of Merck\u2019s patents and other<br \/>\n      protections for innovative products; and the exposure to litigation<br \/>\n      and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2011 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/www.sec.gov\" title=\"www.sec.gov\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Endocyte Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      Certain of the statements made in this press release are forward<br \/>\n      looking, such as those, among others, relating to the company\u2019s<br \/>\n      expectations for seeking regulatory approval and commercial launch of<br \/>\n      its products, including any conditional marketing authorization from the<br \/>\n      EMA, initiation of future clinical trials, and expectations for the<br \/>\n      receipt of milestones, royalties or other profits from the partnership.<br \/>\n      Actual results or developments may differ materially from those<br \/>\n      projected or implied in these forward-looking statements. Factors that<br \/>\n      may cause such a difference include risks that the company may<br \/>\n      experience delays in the completion of its clinical trials (whether<br \/>\n      caused by competition, adverse events, patient enrollment rates,<br \/>\n      unavailability of PLD, regulatory issues or other factors); risks that<br \/>\n      data from its clinical trials may not be indicative of subsequent<br \/>\n      clinical trial results; risks related to the safety and efficacy of the<br \/>\n      company&#8217;s product candidates, the goals of its development activities,<br \/>\n      estimates of the potential markets for its product candidates, estimates<br \/>\n      of the capacity of manufacturing and other facilities required to<br \/>\n      support its product candidates, projected cash needs, and expected<br \/>\n      financial results. More information about the risks and uncertainties<br \/>\n      faced by Endocyte, Inc. is contained in the company&#8217;s periodic reports<br \/>\n      filed with the Securities and Exchange Commission. Endocyte, Inc.<br \/>\n      disclaims any intention or obligation to update or revise any<br \/>\n      forward-looking statements, whether as a result of new information,<br \/>\n      future events or otherwise.\n    <\/p>\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20121127005586r2&amp;sid=sfsite1&amp;distro=nx\"><span class=\"bwct31415\"><\/span><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">Photos\/Multimedia Gallery Available: <\/span><span id=\"mmgallerylink-link\"><a href=\"http:\/\/www.businesswire.com\/multimedia\/home\/20121127005586\/en\/\">http:\/\/www.businesswire.com\/multimedia\/home\/20121127005586\/en\/<\/a><\/span><\/p>\n<p>       Media Contacts:<br \/>Merck<br \/>Pamela Eisele, 908-423-5042<br \/>or<br \/>Endocyte<br \/>Tony        Russo, 212-845-4251<br \/>Monica May, 619-308-6542<br \/>or<br \/>Investor        Contacts:<br \/>Merck<br \/>Alex Kelly, 908-423-4465<br \/>or<br \/>Endocyte<br \/>Paul        Cox, 212-362-1200     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novel personalized treatment approach targets folate receptors on cancer cells Merck, known as MSD outside the United States and Canada (NYSE: MRK), and Endocyte Inc. (NASDAQ: ECYT), today announced that the European Medicines Agency (EMA) has accepted for review the marketing authorization application (MAA) filings for the novel investigational cancer candidate vintafolide (MK-8109\/EC145) and investigational companion diagnostic imaging agent etarfolatide (EC20), for the targeted treatment of patients with folate-receptor positive platinum-resistant ovarian cancer in combination with pegylated liposomal doxorubicin (PLD). Both vintafolide and etarfolatide have been granted orphan drug status by the European Commission. Vintafolide is a proprietary, injectable, conjugate consisting of folate (vitamin B9) linked to a potent vinca alkaloid anti-cancer agent, desacetylvinblastine hydrazide (DAVLBH). Folate is essential for cell division, and cancer cells generally consume higher levels<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[289,56],"class_list":["post-742166","news_item","type-news_item","status-publish","hentry","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck and Endocyte Announce Acceptance for Review of European Marketing Authorization Applications for Vintafolide and Companion Diagnostic Etarfolatide for Folate-Receptor Positive Platinum-Resistant Ovarian Cancer - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-announce-acceptance-for-review-of-european-marketing-authorization-applications-for-vintafolide-and-companion-diagnostic-etarfolatide-for-folate-receptor-positive-platinum-resistant\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck and Endocyte Announce Acceptance for Review of European Marketing Authorization Applications for Vintafolide and Companion Diagnostic Etarfolatide for Folate-Receptor Positive Platinum-Resistant Ovarian Cancer - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Novel personalized treatment approach targets folate receptors on cancer cells Merck, known as MSD outside the United States and Canada (NYSE: MRK), and Endocyte Inc. (NASDAQ: ECYT), today announced that the European Medicines Agency (EMA) has accepted for review the marketing authorization application (MAA) filings for the novel investigational cancer candidate vintafolide (MK-8109\/EC145) and investigational companion diagnostic imaging agent etarfolatide (EC20), for the targeted treatment of patients with folate-receptor positive platinum-resistant ovarian cancer in combination with pegylated liposomal doxorubicin (PLD). Both vintafolide and etarfolatide have been granted orphan drug status by the European Commission. Vintafolide is a proprietary, injectable, conjugate consisting of folate (vitamin B9) linked to a potent vinca alkaloid anti-cancer agent, desacetylvinblastine hydrazide (DAVLBH). Folate is essential for cell division, and cancer cells generally consume higher levels\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-announce-acceptance-for-review-of-european-marketing-authorization-applications-for-vintafolide-and-companion-diagnostic-etarfolatide-for-folate-receptor-positive-platinum-resistant\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:20+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20121127005586r2&amp;sid=sfsite1&amp;distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-endocyte-announce-acceptance-for-review-of-european-marketing-authorization-applications-for-vintafolide-and-companion-diagnostic-etarfolatide-for-folate-receptor-positive-platinum-resistant\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-endocyte-announce-acceptance-for-review-of-european-marketing-authorization-applications-for-vintafolide-and-companion-diagnostic-etarfolatide-for-folate-receptor-positive-platinum-resistant\\\/\",\"name\":\"Merck and Endocyte Announce Acceptance for Review of European Marketing Authorization Applications for Vintafolide and Companion Diagnostic Etarfolatide for Folate-Receptor Positive Platinum-Resistant Ovarian Cancer - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-endocyte-announce-acceptance-for-review-of-european-marketing-authorization-applications-for-vintafolide-and-companion-diagnostic-etarfolatide-for-folate-receptor-positive-platinum-resistant\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-endocyte-announce-acceptance-for-review-of-european-marketing-authorization-applications-for-vintafolide-and-companion-diagnostic-etarfolatide-for-folate-receptor-positive-platinum-resistant\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20121127005586r2&amp;sid=sfsite1&amp;distro=nx\",\"datePublished\":\"2012-11-27T08:30:00+00:00\",\"dateModified\":\"2023-03-22T04:04:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-endocyte-announce-acceptance-for-review-of-european-marketing-authorization-applications-for-vintafolide-and-companion-diagnostic-etarfolatide-for-folate-receptor-positive-platinum-resistant\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-endocyte-announce-acceptance-for-review-of-european-marketing-authorization-applications-for-vintafolide-and-companion-diagnostic-etarfolatide-for-folate-receptor-positive-platinum-resistant\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-endocyte-announce-acceptance-for-review-of-european-marketing-authorization-applications-for-vintafolide-and-companion-diagnostic-etarfolatide-for-folate-receptor-positive-platinum-resistant\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20121127005586r2&amp;sid=sfsite1&amp;distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20121127005586r2&amp;sid=sfsite1&amp;distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-endocyte-announce-acceptance-for-review-of-european-marketing-authorization-applications-for-vintafolide-and-companion-diagnostic-etarfolatide-for-folate-receptor-positive-platinum-resistant\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck and Endocyte Announce Acceptance for Review of European Marketing Authorization Applications for Vintafolide and Companion Diagnostic Etarfolatide for Folate-Receptor Positive Platinum-Resistant Ovarian Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck and Endocyte Announce Acceptance for Review of European Marketing Authorization Applications for Vintafolide and Companion Diagnostic Etarfolatide for Folate-Receptor Positive Platinum-Resistant Ovarian Cancer - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-announce-acceptance-for-review-of-european-marketing-authorization-applications-for-vintafolide-and-companion-diagnostic-etarfolatide-for-folate-receptor-positive-platinum-resistant\/","og_locale":"en_US","og_type":"article","og_title":"Merck and Endocyte Announce Acceptance for Review of European Marketing Authorization Applications for Vintafolide and Companion Diagnostic Etarfolatide for Folate-Receptor Positive Platinum-Resistant Ovarian Cancer - Merck.com","og_description":"Novel personalized treatment approach targets folate receptors on cancer cells Merck, known as MSD outside the United States and Canada (NYSE: MRK), and Endocyte Inc. (NASDAQ: ECYT), today announced that the European Medicines Agency (EMA) has accepted for review the marketing authorization application (MAA) filings for the novel investigational cancer candidate vintafolide (MK-8109\/EC145) and investigational companion diagnostic imaging agent etarfolatide (EC20), for the targeted treatment of patients with folate-receptor positive platinum-resistant ovarian cancer in combination with pegylated liposomal doxorubicin (PLD). Both vintafolide and etarfolatide have been granted orphan drug status by the European Commission. Vintafolide is a proprietary, injectable, conjugate consisting of folate (vitamin B9) linked to a potent vinca alkaloid anti-cancer agent, desacetylvinblastine hydrazide (DAVLBH). Folate is essential for cell division, and cancer cells generally consume higher levels","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-announce-acceptance-for-review-of-european-marketing-authorization-applications-for-vintafolide-and-companion-diagnostic-etarfolatide-for-folate-receptor-positive-platinum-resistant\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:20+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20121127005586r2&amp;sid=sfsite1&amp;distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-announce-acceptance-for-review-of-european-marketing-authorization-applications-for-vintafolide-and-companion-diagnostic-etarfolatide-for-folate-receptor-positive-platinum-resistant\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-announce-acceptance-for-review-of-european-marketing-authorization-applications-for-vintafolide-and-companion-diagnostic-etarfolatide-for-folate-receptor-positive-platinum-resistant\/","name":"Merck and Endocyte Announce Acceptance for Review of European Marketing Authorization Applications for Vintafolide and Companion Diagnostic Etarfolatide for Folate-Receptor Positive Platinum-Resistant Ovarian Cancer - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-announce-acceptance-for-review-of-european-marketing-authorization-applications-for-vintafolide-and-companion-diagnostic-etarfolatide-for-folate-receptor-positive-platinum-resistant\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-announce-acceptance-for-review-of-european-marketing-authorization-applications-for-vintafolide-and-companion-diagnostic-etarfolatide-for-folate-receptor-positive-platinum-resistant\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20121127005586r2&amp;sid=sfsite1&amp;distro=nx","datePublished":"2012-11-27T08:30:00+00:00","dateModified":"2023-03-22T04:04:20+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-announce-acceptance-for-review-of-european-marketing-authorization-applications-for-vintafolide-and-companion-diagnostic-etarfolatide-for-folate-receptor-positive-platinum-resistant\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-announce-acceptance-for-review-of-european-marketing-authorization-applications-for-vintafolide-and-companion-diagnostic-etarfolatide-for-folate-receptor-positive-platinum-resistant\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-announce-acceptance-for-review-of-european-marketing-authorization-applications-for-vintafolide-and-companion-diagnostic-etarfolatide-for-folate-receptor-positive-platinum-resistant\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20121127005586r2&amp;sid=sfsite1&amp;distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20121127005586r2&amp;sid=sfsite1&amp;distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-announce-acceptance-for-review-of-european-marketing-authorization-applications-for-vintafolide-and-companion-diagnostic-etarfolatide-for-folate-receptor-positive-platinum-resistant\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck and Endocyte Announce Acceptance for Review of European Marketing Authorization Applications for Vintafolide and Companion Diagnostic Etarfolatide for Folate-Receptor Positive Platinum-Resistant Ovarian Cancer"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"4535ee00-6c52-44fc-8fc3-580d4379943e","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-and-Endocyte-Announce-Acceptance-for-Review-of-European-Marketing-Authorization-Applications-for-Vintafolide-and-Companion-Diag-79GW0.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742166","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742166\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742166"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742166"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}